163 related articles for article (PubMed ID: 32036070)
21. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL
J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022
[TBL] [Abstract][Full Text] [Related]
22. High
Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
[TBL] [Abstract][Full Text] [Related]
23. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
[TBL] [Abstract][Full Text] [Related]
24. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
25. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
[TBL] [Abstract][Full Text] [Related]
26. Genetic Alterations in Preinvasive Lung Synchronous Lesions.
Ahn S; Lim J; Park SY; Kim H; Kwon HJ; Han YB; Lee CT; Cho S; Chung JH
Cancer Res Treat; 2020 Oct; 52(4):1120-1134. PubMed ID: 32599981
[TBL] [Abstract][Full Text] [Related]
27. Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma.
Wang L; Zhao H; Xu Y; Li J; Deng C; Deng Y; Bai J; Li X; Xiao Y; Zhang Y
Int J Cancer; 2019 Apr; 144(7):1723-1734. PubMed ID: 30226269
[TBL] [Abstract][Full Text] [Related]
28. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide investigation of the clinical significance and prospective molecular mechanism of minichromosome maintenance protein family genes in patients with Lung Adenocarcinoma.
Liu K; Kang M; Liao X; Wang R
PLoS One; 2019; 14(7):e0219467. PubMed ID: 31323040
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
[TBL] [Abstract][Full Text] [Related]
31. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
32. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
33. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
Liu X; Chen L; Zhang T
Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
[TBL] [Abstract][Full Text] [Related]
34. Identification of CAV1 and DCN as potential predictive biomarkers for lung adenocarcinoma.
Yan Y; Xu Z; Qian L; Zeng S; Zhou Y; Chen X; Wei J; Gong Z
Am J Physiol Lung Cell Mol Physiol; 2019 Apr; 316(4):L630-L643. PubMed ID: 30604627
[TBL] [Abstract][Full Text] [Related]
35. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
36. Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas.
Menor M; Zhu Y; Wang Y; Zhang J; Jiang B; Deng Y
BMC Med Genomics; 2019 Jan; 12(Suppl 1):24. PubMed ID: 30704450
[TBL] [Abstract][Full Text] [Related]
37. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Jang JS; Lee A; Li J; Liyanage H; Yang Y; Guo L; Asmann YW; Li PW; Erickson-Johnson M; Sakai Y; Sun Z; Jeon HS; Hwang H; Bungum AO; Edell ES; Simon VA; Kopp KJ; Eckloff B; Oliveira AM; Wieben E; Aubry MC; Yi E; Wigle D; Diasio RB; Yang P; Jen J
Sci Rep; 2015 May; 5():9755. PubMed ID: 25985019
[TBL] [Abstract][Full Text] [Related]
38. Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD.
Xiao D; Li F; Pan H; Liang H; Wu K; He J
Sci Rep; 2017 May; 7(1):2121. PubMed ID: 28522810
[TBL] [Abstract][Full Text] [Related]
39. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
40. Elevated Expression of
Hu P; Huang Y; Gao Y; Yan H; Li X; Zhang J; Wang Y; Zhao Y
DNA Cell Biol; 2020 Apr; 39(4):522-532. PubMed ID: 32040344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
